Corcept Therapeutics Set to Report Q2 Results Amid Key Drug Expansion
Event summary
- Corcept Therapeutics will report second-quarter financial results on July 29, 2026.
- The company recently launched Lifyorli™ for platinum-resistant ovarian cancer in 2026.
- Corcept has over 1,000 proprietary selective cortisol modulators in development.
The big picture
Corcept Therapeutics is expanding its footprint in oncology with the FDA approval of Lifyorli™, complementing its established position in Cushing’s syndrome. The company’s focus on cortisol modulation positions it in a niche but growing segment of precision medicine, where execution in commercialization and clinical development will be critical.
What we're watching
- Commercial Execution
- How Corcept will scale Lifyorli™ adoption in platinum-resistant ovarian cancer.
- Pipeline Progress
- The pace at which Corcept advances trials in ALS and liver disease.
- Financial Performance
- Whether Q2 results reflect sustained revenue growth from Korlym® and Lifyorli™.
Related topics